Bayer AG's decision to reach outside the company to bring in Thermo Fisher's Marijn Dekkers as its new CEO has the analysts buzzing about the likelihood of a substantial restucturing at the drug and chemical giant. "It looks like Bayer is getting prepared for corporate transformation," UBS AG analyst Fabian Wenner tells Bloomberg. "Dekkers is an expert in corporate restructuring. By focusing on health care, investors could have more visibility on each single element." Report